Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)

Part of paid clinical trials in Chicago, Illinois.

Sponsor
University of Chicago
Study ID
NCT03990961
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Pembrolizumab — DRUG
    Subjects will receive pembrolizumab treatment at a dose of 200mg IV every 3 weeks for a duration of 2 years (35 cycles).

Study Details

A non randomized, unblinded, open label phase 2 study to investigate the efficacy of pembrolizumab in patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL) with PD-L1 genetic alterations

Key Dates

Start date
Sep 4, 2019
Status verified
Feb 2026
Primary completion
Apr 1, 2024
Completion
Apr 1, 2024

Study Design

Enrollment
5 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Pembrolizumab Treatment

Primary Outcome Measure

Overall Response Rate (ORR) to Pembrolizumab Treatment Compared to Historical Controls. [ Time Frame: 4.5 years ]

Locations (1)

FacilityCityStateZIPSite coordinators
The University of Chicago MedicineChicagoIllinois60637-

Related coverage on Hipa.ai

Find similar trials in Chicago, IL

By research site
The University of Chicago Medicine· Chicago, IL

Related Studies